Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Sell
28
VYGR Quote, Financials, Valuation and Earnings
Last price:
$4.28
Seasonality move
:
-3.47%
Day range:
$4.23 - $4.40
52-week range:
$2.65 - $6.69
Dividend yield:
0%
P/E ratio:
6.11x
P/S ratio:
7.99x
P/B ratio:
1.08x
Volume:
410.1K
Avg. volume:
485.3K
1-year change:
-31.41%
Market cap:
$238M
Revenue:
$80M
EPS (TTM):
-$2.17
Analysts' Opinion
-
Consensus RatingVoyager Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.00, Voyager Therapeutics, Inc. has an estimated upside of 250.47% from its current price of $4.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $4.28.
Fair Value
-
According to the consensus of 12 analysts, Voyager Therapeutics, Inc. has 250.47% upside to fair value with a price target of $15.00 per share.
VYGR vs. S&P 500
-
Over the past 5 trading days, Voyager Therapeutics, Inc. has overperformed the S&P 500 by 4.32% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Voyager Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Voyager Therapeutics, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Voyager Therapeutics, Inc. reported revenues of $13.4M.
Earnings Growth
-
Voyager Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Voyager Therapeutics, Inc. reported earnings per share of -$0.47.
Enterprise value:
67.4M
EV / Invested capital:
--
Price / LTM sales:
7.99x
EV / EBIT:
-14.16x
EV / Revenue:
2.15x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.57x
Price / Operating cash flow:
50.49x
Enterprise value / EBITDA:
-9.09x
Gross Profit (TTM):
$27.3M
Return On Assets:
-35.56%
Net Income Margin (TTM):
-404.85%
Return On Equity:
-46.39%
Return On Invested Capital:
-40.22%
Operating Margin:
-228.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $158.4M | $163.8M | $31.3M | $24.6M | $13.4M | |
| Gross Profit | $154.5M | $158.7M | $27.3M | $23.5M | $12.4M | |
| Operating Income | $43.4M | $9.1M | -$140.2M | -$13.8M | -$30.6M | |
| EBITDA | $47.3M | $14.1M | -$136.2M | -$12.6M | -$29.7M | |
| Diluted EPS | $1.23 | $0.72 | -$2.17 | -$0.16 | -$0.47 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $126.2M | $146.9M | $261.9M | $373.4M | $219.6M | |
| Total Assets | $184.8M | $182.5M | $294.7M | $426M | $288.3M | |
| Current Liabilities | $26.7M | $73.2M | $61.7M | $44.2M | $35.5M | |
| Total Liabilities | $97.4M | $102.7M | $118.4M | $95.7M | $68.5M | |
| Total Equity | $87.4M | $79.8M | $176.2M | $330.3M | $219.8M | |
| Total Debt | $45.3M | $21M | $17.9M | $38.4M | $30.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $89.4M | -$24.5M | -$116.7M | -$28M | -$31M | |
| Cash From Investing | -$154.4M | -$40.8M | $50.8M | $64.4M | $34.9M | |
| Cash From Financing | $33.5M | $113.9M | $1.3M | $14K | $85K | |
| Free Cash Flow | $86M | -$28.7M | -$118.9M | -$28.2M | -$31.3M | |
VYGR
Sector
Market Cap
$238M
$28.5M
Price % of 52-Week High
63.98%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
0.18%
-1.33%
1-Year Price Total Return
-31.41%
-20.32%
Beta (5-Year)
1.236
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.08
200-day SMA
Buy
Level
$3.75
Bollinger Bands (100)
Buy
Level
3.46 - 4.68
Chaikin Money Flow
Sell
Level
-312.6K
20-day SMA
Buy
Level
$4.13
Relative Strength Index (RSI14)
Buy
Level
51.50
ADX Line
Buy
Level
23.77
Williams %R
Neutral
Level
-22.695
50-day SMA
Sell
Level
$4.51
MACD (12, 26)
Buy
Level
0.84
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Sell
Level
-2.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.0314)
Sell
CA Score
(Annual)
Level (-0.3791)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-1.3519)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Stock Forecast FAQ
In the current month, VYGR has received 12 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VYGR average analyst price target in the past 3 months is $15.00.
-
Where Will Voyager Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Voyager Therapeutics, Inc. share price will rise to $15.00 per share over the next 12 months.
-
What Do Analysts Say About Voyager Therapeutics, Inc.?
Analysts are divided on their view about Voyager Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Voyager Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Voyager Therapeutics, Inc.'s Price Target?
The price target for Voyager Therapeutics, Inc. over the next 1-year time period is forecast to be $15.00 according to 12 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VYGR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Voyager Therapeutics, Inc. is a Buy. 12 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VYGR?
You can purchase shares of Voyager Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Voyager Therapeutics, Inc. shares.
-
What Is The Voyager Therapeutics, Inc. Share Price Today?
Voyager Therapeutics, Inc. was last trading at $4.28 per share. This represents the most recent stock quote for Voyager Therapeutics, Inc.. Yesterday, Voyager Therapeutics, Inc. closed at $4.28 per share.
-
How To Buy Voyager Therapeutics, Inc. Stock Online?
In order to purchase Voyager Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get VYGR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VYGR
Sector
P/E ratio
6.11x
23.75x
PEG ratio
0.00x
-0.01x
P/B ratio
1.08x
1.83x
Price / LTM sales
7.99x
1.60x
Growth Metrics
VYGR
Sector
Revenue growth
-45.74%
4.85%
Earnings growth
-203.46%
11.11%
Revenue (5-year growth)
-5.18%
6.45%
Earnings forecast
-$0.49
-$0.20
Profitability
VYGR
Sector
Profitability FY 2024
$75.3M
$3.6M
Return on invested capital
-40.22%
-30.98%
Return on assets
-35.56%
-27.62%
Return on equity
-46.39%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
16
Estimated Next Earnings Date
Feb
9
Balance Sheet
VYGR
Sector
Total cash
$208.9M
$27.2M
Short term investments
$195.3M
$25.7M
Total assets
$393.1M
$79.7M
Long term debt
$30.5M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
